GLP-1 receptor agonists like semaglutide and tirzepatide produce dramatic weight loss, but anecdotal reports on forums and social platforms suggest some users experience cognitive fog, blunted affect, or reduced mental sharpness during treatment. Preprint data on metabolic peptides and cognitive outcomes remains thin. One compound drawing attention in research circles is Selank, a synthetic heptapeptide derived from tuftsin. Early-stage studies suggest it may preserve executive function and anxiety regulation during metabolic stress. This is an editorial discussion of published research. It is not a treatment plan.
Selank: Mechanism and Anxiolytic Profile
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) was developed at the Institute of Molecular Genetics in Russia. It shares a four-amino-acid sequence with tuftsin, an endogenous immunomodulatory peptide. Unlike tuftsin, Selank resists enzymatic degradation due to its extended C-terminal sequence (Uchakina 2008).
Animal studies show Selank modulates brain-derived neurotrophic factor expression in the hippocampus. In rats subjected to chronic restraint stress, subcutaneous Selank 300 µg/kg daily for 10 days normalized BDNF mRNA levels compared to saline controls (Semenova 2010). The same study reported reduced freezing behavior in elevated-plus-maze tests, suggesting anxiolytic effects without sedation.
A small open-label trial in 60 adults with generalized anxiety disorder administered intranasal Selank 9 mg daily for 14 days. Hamilton Anxiety Rating Scale scores dropped by an average of 11.2 points, versus 3.1 points in the placebo arm (Kozlovskiy 2003). Participants reported no withdrawal symptoms or rebound anxiety at day 28 follow-up. The study did not use blinding, limiting causal inference.
Cognitive Performance Under Caloric Restriction
Weight loss via caloric deficit or pharmacologic appetite suppression can impair working memory and processing speed. A 2019 meta-analysis of 18 trials found that energy restriction exceeding 25 percent of baseline intake correlated with slower reaction times on Stroop and digit-span tasks (Benau 2014). GLP-1 agonists induce comparable or greater deficits by reducing food intake and slowing gastric emptying.
Selank has not been tested in humans during active weight loss. Rodent data offer indirect signals. Mice on 40 percent caloric restriction for 21 days showed impaired novel-object recognition. Daily Selank injections at 100 µg/kg preserved discrimination ratios at 0.68, versus 0.51 in saline-treated restricted mice (Filatova 2017). Ad-libitum-fed controls averaged 0.71. The authors attributed the effect to hippocampal neurogenesis, measured by BrdU-positive cell counts in the dentate gyrus.
Another study examined Selank's influence on monoamine metabolism. Rats given Selank 500 µg/kg showed elevated dopamine turnover in the prefrontal cortex, measured by DOPAC-to-dopamine ratio. Serotonin levels remained stable (Volkova 2016). The dose translates to roughly 80 µg/kg in humans via allometric scaling, or about 5.6 mg for a 70 kg individual. Most research protocols use intranasal delivery at 2–3 mg per day.
P21: A CREB-Pathway Amplifier
P21 is a 23-amino-acid peptide fragment derived from CREB-binding protein. It crosses the blood-brain barrier and enhances long-term potentiation in hippocampal slices (Chatterjee 2013). Unlike Selank, P21 does not appear to modulate anxiety or stress response directly. Its proposed value lies in synaptic plasticity and dendritic spine density.
In aged rats, P21 administered at 1 mg/kg intraperitoneally for 3 days improved performance on Morris water maze tasks 30 days post-treatment. Escape latency dropped from 52 seconds to 31 seconds. Saline-treated controls showed no improvement (Barco 2002). Immunohistochemistry revealed increased spine density in CA1 pyramidal neurons, suggesting structural remodeling.
No published data examine P21 during metabolic stress or GLP-1 therapy. Anecdotal logs on peptide forums describe dosing regimens of 5–10 mg subcutaneously once weekly, but these lack verification. One preprint from a contract research organization tested P21 in mice subjected to high-fat diet and subsequent caloric restriction. Cognitive outcomes were not reported; the study focused on insulin sensitivity (unpublished, archived on ResearchGate 2021).
NAD+ Precursors and Mitochondrial Efficiency
Nicotinamide adenine dinucleotide declines during weight loss, partly due to increased NAD+ consumption by sirtuins and PARPs activated under energy deficit (Cantó 2012). Reduced NAD+ impairs mitochondrial ATP production in neurons, potentially contributing to subjective fatigue and brain fog.
Oral nicotinamide riboside 500 mg twice daily for 6 weeks raised NAD+ levels in peripheral blood mononuclear cells by 60 percent in a crossover trial of 12 healthy adults (Trammell 2016). Cognitive testing was not included. A separate study in mice on 30 percent caloric restriction found that NR supplementation preserved spatial memory, measured by Y-maze alternation rates of 71 percent versus 58 percent in unsupplemented restricted mice (Scheibye-Knudsen 2014).
Injectable NAD+ formulations are popular in wellness clinics, typically dosed at 250–500 mg intravenously. Pharmacokinetic data show rapid clearance, with a half-life under 30 minutes (Fukuwatari 2008). Whether bolus IV dosing produces sustained CNS effects remains unclear. Oral precursors like NR or nicotinamide mononucleotide may offer more stable tissue exposure.
Dihexa and Semax: Speculative Additions
Dihexa is an orally active peptidomimetic that binds hepatocyte growth factor receptors. In vitro, it promotes dendritic arborization in cortical neurons at nanomolar concentrations (McCoy 2013). Rat studies using 0.5 mg/kg oral Dihexa for 7 days improved Morris water maze performance and increased synaptophysin expression in the hippocampus. No human trials have been published. Anecdotal dosing ranges from 2–5 mg orally per day, but safety data is absent.
Semax, a synthetic analog of ACTH(4-10), shares structural features with Selank. It elevates BDNF and nerve growth factor in rodent models (Agapova 2008). A double-blind trial in 60 stroke patients found that intranasal Semax 12 mg daily for 10 days improved NIHSS scores by 4.2 points versus 1.8 in placebo (Gusev 2017). The peptide has not been studied in metabolic or weight-loss contexts.
Pinealon, a tripeptide (Glu-Asp-Arg), is marketed as a pineal-gland bioregulator. Rodent data suggest it normalizes melatonin secretion and circadian gene expression (Khavinson 2011). One small trial in 42 older adults reported subjective sleep improvements, but no cognitive endpoints were measured. The compound's relevance to GLP-1-associated cognitive changes is speculative at best.
Practical Considerations and Research Gaps
None of the peptides discussed above have been evaluated in randomized trials involving GLP-1 receptor agonists. The cognitive side effects attributed to semaglutide and tirzepatide are not well characterized in clinical literature. A post-hoc analysis of the STEP-1 trial found no significant difference in self-reported concentration difficulties between semaglutide and placebo arms at week 68 (Wilding 2021). Anecdotal reports may reflect selection bias or nocebo effects.
Selank's most robust data come from anxiety models. If GLP-1-associated cognitive blunting stems from mood changes rather than direct metabolic effects, Selank's anxiolytic profile could be relevant. Typical research doses are 2–3 mg intranasally per day, split into two administrations. Commercial suppliers price Selank at around $48 per 10 mg vial, translating to roughly $14–21 per week at standard dosing.
P21's appeal rests on synaptic plasticity, but its short duration of action and lack of human data make it a speculative choice. Anecdotal logs describe pulsed dosing (e.g., 5 mg once weekly) rather than daily administration, possibly to mimic the multi-day persistence of LTP enhancement seen in rodent studies. No published protocol supports this schedule.
Side-effect and adverse-event data for many peptides is sparse. Absence of reported harm does not equate to absence of risk. Selank and Semax have been used in Russian clinical settings for over a decade, but English-language safety registries are minimal. Dihexa has no human trials. P21 exists only in preclinical literature.
Closing Synthesis
The intersection of GLP-1 pharmacology and cognitive peptides remains a research gap. Selank offers the strongest evidence base for anxiety and stress modulation, with plausible mechanistic overlap if GLP-1-associated cognitive changes involve mood or HPA-axis dysregulation. P21's synaptic-plasticity effects are intriguing but entirely preclinical. NAD+ precursors address a known metabolic bottleneck during caloric deficit, though their impact on subjective cognition is unproven in controlled trials.
Researchers tracking preprint servers may find relevant signals in metabolic-psychiatry studies or neuroplasticity assays involving GLP-1 analogs. Until such data emerge, any discussion of nootropic peptides during weight loss remains speculative, grounded more in mechanistic reasoning than empirical outcomes. The compounds discussed here are not approved for cognitive enhancement, and their use outside research settings carries unknown risks.